27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of small-cap oncology biotech Puma Biotechnology Inc (NASDAQ:PBYI) are sinking to their lowest level since November following the release of its first-quarter results.
Nerlynx Numbers Disappoint
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
While Puma beat consensus earnings and revenue estimates, it appears to be an update on Nerlynx, its first commercial product, that's sending the stock into freefall.
Puma said its product revenues stem entirely from sales of the treatment, which has been approved for treating early stage, previously treated HER 2+ breast cancer.
The FDA approved the once-daily oral tablet in July 2017.
A Nerlynx sales miss in the third quarter of 2018 sent Puma's shares down by about 50 percent Nov. 2.
Nerlynx revenues, though increasing 27 percent year-over-year, represented a 25-percent drop from the $61.1 million reported for the fourth quarter of 2018.
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
"Puma experienced lower than expected net product revenue in the first quarter of 2019," Puma CEO Alan Auerbach said in a statement.
The decline was attributed to an increase in expenses charged against gross revenue and an increase in patients discontinuing Nerlynx treatment.
A string of downgrades followed the earnings announcement: Citigroup downgraded the stock from Buy to Neutral, while Cantor Fitzgerald downgraded the stock from Overweight to Neutral and reduced the price target to $20.
Price Action
Puma shares were down 36.86 percent at $18.95 at the time of publication Friday.
Related Links:
Bristol-Myers Squibb's Opdivo Stumbles In Late-Stage Brain Cancer Study
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.